Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2008

View Archived Issues

Studies show analgesic efficacy of ARRY-797 in postsurgical dental pain

Pooled GOUT 1 and GOUT 2 data detail effects of pegloticase

Recent University of Aberdeen patent discloses novel agents for bone disorders

New therapeutic agents for neurological disorders reported in recent patent literature

Thalidomide not effective in treating amyotrophic lateral sclerosis

Antimicrobial activity of host defense peptide mimetics described

NIH awards SBIR grant to BioSante to develop pulmonary delivery of IFN-alpha

Boehringer Ingelheim commences phase III pivitol program for Vargatef

DSMC authorizes Bioniche to continue phase III Urocadin trial in bladder cancer

Innocoll receives FDA fast track designation for Gentamicin Surgical Implant

Relistor approved in Australia for opioid-induced constipation

Life Science Pharmaceuticals enters into agreement with Abbott for Antibody 806

Eli Lilly and United Therapeutics enter license and supply agreement for PAH

SciClone reaches agreement with FDA on SPA for phase III thymalfasin trial

Solvay discontinues R&D activities of antiobesity compound SLV-319

Theratechnologies completes treatment of patients in extension phase of tesamorelin trial

Biotie acquires Elbion NV's subsidiary Elbion GmbH

Proteome Systems changes name to Tyrian Diagnostics

Affymax completes enrollment in EMERALD 2 phase III clinical trial of Hematide

Serenity initiates phase II clinical study of intranasal drug for urology indication

Novel dopamine D3 receptor agonists and antagonists described by Pfizer

Preclinical activity of PF-03800130 shows benefit in bipolar disorder-associated mood symptoms

Phase II results with rivaroxaban in acute coronary syndromes reported

New compounds for hypogonadism described in recent GSK patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...